Lantheus Holdings Inc. reported worldwide revenue of $384.0 million for the third quarter of 2025. The company recorded GAAP fully diluted earnings per share of $0.41 and adjusted fully diluted earnings per share of $1.27. Free cash flow for the quarter was $94.7 million. During the period, Lantheus closed the acquisition of Life Molecular Imaging, expanding its commercial portfolio and capabilities in nuclear medicine. The company also announced upcoming PDUFA dates for its new formulation of piflufolastat F 18 PSMA PET imaging agent, MK-6240 tau-targeted PET imaging agent, and LNTH-2501 Ga 68 PET diagnostic imaging kit. Additionally, Lantheus disclosed a leadership transition plan, with CEO Brian Markison set to retire at the end of 2025 and the board initiating a CEO search.